Factors influencing plasma lipid profiles including lipoprotein (a) concentrations in renal transplant recipients

Transplant International

Volumn 9, Issue 3, 1996, Pages 221-226

  Wheeler, David C ^a,d   Morgan, Ruth ^b   Thomas, David M ^a   Seed, Mary ^c   Rees, Alan ^b   Moore, Richard H ^a  

^a Cardiff Royal Infirmary   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Apoprotein (a), kidney transplantation; Cholesterol, kidney transplantation; Kidney transplantation, cholesterol; Kidney transplantation, hyperlipidaemia; Lipoprotein (a), kidney transplantation

Indexed keywords

APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CREATININE; CYCLOSPORIN; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; STEROID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CREATININE CLEARANCE; DIURETIC THERAPY; DRUG EFFECT; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS; APOLIPOPROTEINS B; APOPROTEIN(A); CHOLESTEROL; CREATININE; CYCLOSPORINE; DIURETICS; FEMALE; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPOPROTEIN(A); LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; PHENOTYPE; PREDNISOLONE; REGRESSION ANALYSIS; RISK FACTORS; TRIGLYCERIDES;

EID: 0029981935     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00335389     Document Type: Article

References (46)

1. Allain CC, Poon LS, Chan CSG. Richmond W. Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20: 470-475
2. Ames RP (1986) The effect of antihypcrtcnsive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs. Drugs 32: 335-357
3. Armstrong VW. Cremer P, Eberle E, Manke A, Schulze F, Wieland H. Kreuzer H, Seidel D (1986) The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 62: 249-257
4. Ballantyne CM, Podet EJ, Patsch WP, Harati Y. Appel V, Gotto AM, Young JB (1989) Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 262: 53-56
5. Bittar AE ,Ratcliffe PJ, Richardson AJ, Raine AEG, Jones L, Yudkin PL, Carter R, Mann JI. Morris PJ (1990) The prevalence of hypcrlipidaemia in renal transplant recipients. Transplantation 50:987-992
6. Black IW, Wilcken DEL (1992) Decreases in apoliprotein (a) after renal transplantation: implications for lipoprotien (a) metabolism. Clin Chem 38: 353-357
7. Boerwinkle E. Menzel HJ, Kraft HG, Utcrmann G (1989) Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation. Hum Genet 82: 73-78
8. Brown JH, Anwar N, Short CD. Bhatnager D, Mackness MI, Hunt LP, Durrington PN (1993) Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant 8: 863-867
9. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256: 2835-2838
10. Chan MK, Varghese Z, Persaud JW, Fernando ON, Moorhead JF (1981) The role of multiple pharmaco-therapy in the pathogenesis of hyperlipidaemia after renal transplantation. Clin Nephrol 15: 309-313
11. Cressman MD. Heyka RJ, Paganini EP, O'Neill J, Skibinski CI, Hoff HF (1992) Lipoprotein (a) is an independent risk factor for cardiovascular disease in haemodialysis patients. Circulation 86: 475-482
12. Dieplinger H, Lackner C. Kronenberg F. Sandholzer C, Lhotta K. Hoppichler F, Graf H, König P (1993) Elevated plasma concentrations of lipoprotein (a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein (a). J Clin Invest 91: 397-401
13. Dimény E, Fellström B, Larsson E, Tufveson G. Lithell H (1993) Chronic vascular rejection and hyperlipoproteinemia m renal transplant patients. Clin Transplant 7: 482-490
14. Friedewald WT, Levy RI, Fredickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502
15. Haffner SM, Gruber KK, Aldrete G, Morales PA. Stern MP, Tuttle KR (1992) Increased lipoprotein (a) concentrations in chronic renal failure. J Am Soc Nephrol 3:1156-1162
16. Harris KPG, Russell GI, Parvin SD, Veitch PS, Walls J (1986) Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. BMJ 292:16
17. Heimann P, Josephson MA, Fellner SK, Thistlethwaite JR, Stuart FP, Dasgupta A (1991) Elevated lipoprotein (a) levels in renal transplantation and haemodialysis patients. Am J Nephrol 11: 470-474
18. Irish AB, Simons LA, Savdie E, Hayes JM, Simons J (1992) Lipoprotein (a) levels in chronic renal disease states, dialysis and transplantation. Aust N Z J Med 22: 243-248
19. Jackson JM, Lee HA (1982) The role of propranolol therapy and proteinuria in the aetiology of post renal transplantation hyperlipidaemia. Clin Nephrol 18: 95-100
20. Kapelrud H, Bangstad H-J, Dahl-Jørgensen K, Berg K, Hanssen KF (1991) Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria. BMJ 303: 675-678
21. Kasiske BL (1988) Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 84: 985-992
22. Kasiske BL, Umen AJ (1987) Persistent hyperlipidaemia in renal transplant patients. Medicine (Baltimore) 66:309-316
23. Lowry RP, Soltys G, Mangel R, Kwiterovitch P, Sniderman AD (1987) Type II hyperlipoproteinaemia. hyperapobetalipoproteinaemia, and hyperalphaliproteinaemia following renal transplantation: prevalence and precipitating factors. Transplant Proc 19: 2229-2232
24. Markell MS, Friedman EA (1989) Hyperlipidaemia after organ transplantation. Am J Med 87 [Suppl 5N]: 61N-67N
25. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D (1986) Serum cholesterol blood pressure and mortality: implications from a cohort of 361,622 men. Lancet II: 933-936
26. Moorhead JF, Wheeler DC, Varghese Z (1989) Glomerular structures and lipids in progressive renal disease. Am J Med 87 [Suppl 5N]: 12-20N
27. Morgan R, Bishop AJ, Young WT, Ephraim DC, Matthews SB, Rees A (1992) The relationship between apolipoprotein (a), lipid and lipoprotein levels and the risk of coronary artery disease. Cardiovasc Risk Factors 2: 105-111
28. Muldoon MF, Manuck SB, Matthews KA (1990) Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 301: 309-314
29. Pirsch JD, D'Alessandro AM, Sollinger HW, Knechtle SJ, Reed A, Kalayoglu M, Bclzcr FO (1992) Hypcrlipidaemia and transplantation: etiologic factors and therapy. J Am Soc Nephrol 2: S238-S242
30. Pollare T, Lithel H, Berne C (1989) A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321: 868-873
31. Roseneren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H (1990) Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ 301: 1248-1251
32. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G (1992) Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 12:1214-1226
33. Savdie E, Gibson JC, Stewart JH, Simons LA (1979) High-density lipoprotein in chronic renal failure and after renal transplantation. BMJ 1: 928-930
34. Scanu AM, Fless GM (1990) Lipoprotein (a): heterogeneity and biological relevance. J Clin Invest 85: 1709-1715
35. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H (1992) High serum lipoprotein (a) concentrations in uraemic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 38: 271-276
36. Simons LA (1986) Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries. Am J Cardiol 57: 5-10G
37. Stenvinkel P, Berglund L, Heimbürger O, Pettersson E, Alvestrand A (1993) Lipoprotein (a) in nephrotic syndrome. Kidney Int 44:1116-1123
38. The US Renal Data system (1990) Excerpts from United States Renal Data System 1990 annual report: VI. Survival and mortality. Am J Kidney Dis 16: 44-52
39. Thillet J, Faucher C. Issad B, Allouache M, Chapman J, Jacobs C (1993) Lipoprotein (a) in patients treated by continuous ambulatory peritoneal dialysis. Am J Kidney Dis 22: 226-232
40. Thomas ME, Freestone A, Varghese Z, Persaud JW, Moorhead JF (1992) Lipoprotein (a) in patients with proteimma, Nephrol Dial Transplant 7: 597-601
41. Vathsala A, Weinberg RB, Schoenberg L, Grevel J, Dunn J, Goldstein RA, Van Buren CT, Lewis RM, Kahan BD (1989) Lipid abnormalities in renal transplant recipients treated with cyclosporin. Transplant Proc 21: 3670-3673
42. Wahlefeld AW (1974) Triglycerides. Determination after enzymatic hydrolysis. In: Bergmeyer HU (ed) Methods of enzymatic analysis. 2nd English edn. Verlag Chemie, Weinheim/Academic Press, New York, pp 1831-1835
43. Warnick GR, Nguyen T, Albers AA (1985) Comparison of improved precipitation methods for quantification of high density lipoprotein cholesterol. Clin Chem 31: 217-222
44. Webb AT, Plant M, Reaveley DA, O'Donnell M, Luck VA, O'Connor B. Seed M, Brown EA (1992) Lipid and lipoprotein (a) concentrations in renal transplant patients. Nephrol Dial Transplant 7: 636-641
45. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA (1993) Does cyclosporin increase lipoprotein (a) concentrations in renal transplant recipients? Lancet 341: 268-270
46. Wheeler DC, Bernard DB (1994) Lipid abnormalities in the nephrotic syndrome: causes, consequences and treatment. Am J Kidney Dis 23: 331-346